Active substanceCeftriaxoneCeftriaxone
Similar drugsTo uncover
  • Azaran
    powdersolution w / m in / in 
    Hemofarm AD     Serbia
  • Axon
    powder w / m in / in 
  • Betasporin
    powdersolution w / m in / in 
    Laboratorios Atral SA     Portugal
  • Biotrakson
    powdersolution w / m in / in 
  • Broadssef-S
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • IFICEF®
    powder w / m in / in 
  • Lendacin®
    powder d / infusion 
    Lek dd     Slovenia
  • Lifaxon
    powdersolution w / m in / in 
    FARMGID CJSC     Russia
  • Medaxon
    powder w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Movigip®
    powder w / m in / in 
  • Oframax®
    powdersolution w / m in / in 
  • Rocefin®
    powder w / m 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder in / in 
  • Rocefin®
    powder w / m in / in 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder d / infusion 
    Hoffmann-La Roche Ltd.     Switzerland
  • Steritsef®
    powdersolution for injections 
  • Tertsef®
    powdersolution w / m in / in 
    Aktavis, AO     Iceland
  • TOROCEF®
    powdersolution w / m in / in 
  • Triacson
    powdersolution w / m in / in 
  • Chizon
    powdersolution w / m in / in 
    Shin Pung Pharmaceutical Co., Ltd.     The Republic of Korea
  • Cefaxon
    powdersolution w / m in / in 
    Lupine Co., Ltd.     India
  • Cefatrine
    powdersolution w / m in / in 
  • Cefogram®
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriaxone
    powdersolution d / infusion 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Ceftriaxone
    powdersolution w / m in / in 
    RUZFARMA, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    RAFARMA, CJSC     Russia
  • Ceftriaxone
    powdersolution
    Mapichem AG     Switzerland
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    LEKKO, ZAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    Vertex Exports     India
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOCHEMIST, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution
    SYNTHESIS, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    Company DEKO, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    MAKIZ-PHARMA, LLC     Russia
  • Ceftriaxone
    powder w / m in / in 
    HIMFARM, JSC     Kazakhstan
  • Ceftriaxone
    powder w / m in / in 
  • Ceftriaxone Danson
    powdersolution w / m in / in 
  • Ceftriaxone DS
    powdersolution
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Protek
    powdersolution w / m in / in 
  • Elf Ceftriaxone
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Ceftriaxone-Vial
    powdersolution w / m in / in 
    VIAL, LLC     Russia
  • Ceftriaxone-Jodhas
    powdersolution w / m in / in 
  • Ceftriaxone-CmP
    powdersolution w / m in / in 
  • Ceftriaxone-LEXMM®
    powdersolution w / m in / in 
  • Dosage form: & nbspPowder for the preparation of solution for intravenous and intramuscular injection.
    Composition:Active substance: ceftriaxone sodium trisecihydrate, equivalent to ceftriaxone 1 g.
    Description:From white to white with a yellowish hue of color powder.
    Pharmacotherapeutic group:Antibiotic-cephalosporin.
    ATX: & nbsp

    J.01.D.D.04   Ceftriaxone

    Pharmacodynamics:

    Ceftriaxone - cephalosporin antibiotic III Generations for parenteral use, has a bactericidal effect, inhibits the synthesis of the cell membrane, in vitro suppresses the growth of most gram-positive and gram-negative microorganisms. Ceftriaxone is resistant to beta-lactamase enzymes (both penicillinase and cephalosporinase, produced by the majority of Gram-positive and Gram-negative bacteria). Effective against the following microorganisms:

    Gram-positive

    Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus A (Streptococcus pyogenes), Streptococcus V (Streptococcus agalactiae), Streptococcus viridans, Strep­tococcus bovis.

    Note: Staphylococcus spp., resistant to methicillin, is resistant to cephalosporins, including ceftriaxone. Most strains of enterococci (for example, Streptococ­cus faecalis) also resistant to ceftriaxone.

    Gram-negative

    Aeromonas spp., Alcaligenes spp., Branhamella catarrhalis, Citrobacter spp., Enterobacter spp. (not­which strains are stable), Escherichia coli, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella spp. (at Tom number of Klebsiella pneumoniae), Moraxella spp., Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Plesiomonas shigelloides, Proteus mirabilis, Proteus vulgaris, Providencia spp., Salmonella spp. (at Tom number of Salmonella typhi), Seifatia spp. (at Tom number of Serratia marcescens), Shigella spp., Vibrio spp. (at Tom number of Vibrio cholerae), Yersinia spp. (at Tom number of Yersinia enterocolitica).

    Note: many strains of these microorganisms, which in the presence of other antibiotics, for example, penicillins, first-generation cephalosporins and aminoglycosides, are multiplying steadily, are sensitive to ceftriaxone. Treponema pallidum is sensitive to ceftriaxone as in vitro, and in experiments on animals. According to clinical data, in the primary and secondary syphilis, a good efficacy of ceftriaxone

    Anaerobic pathogens

    Bacteroides spp. (including some strains Bacteroides fragilis), Clostridium spp. (at Tom number of Clostridium difficile), Fusobacterium spp. (Besides Fusobacterium mostiferum, Fusobacterium varium), Peptococcus spp., Peptostreptococcus spp.

    Note: some strains of many Bacteroides spp. (eg, Bacteroides fragilis), Developing beta-lactamase, resistant to ceftriaxone.To determine the sensitivity of microorganisms, discs containing ceftriaxone, since it is shown that in vitro to classical cephalosporins, certain strains of pathogens can be stable.

    With very few exceptions, strains Pseudomonas aeruginosa resistant to ceftriaxone.

    Pharmacokinetics:
    With parenteral administration ceftriaxone well penetrates into tissues and body fluids.
    Ceftriaxone is characterized by a long half-life of about 8 hours. The area under the concentration curve - time in the blood serum for intravenous and intramuscular injection coincide. This means that the bioavailability of ceftriaxone when administered intramuscularly is 100%. With intravenous administration ceftriaxone quickly diffuses into the interstitial fluid, where its bactericidal action against pathogens sensitive to it persists for 24 hours. Ceftriaxone reversibly binds to albumin and this binding is inversely proportional to the concentration: for example, when the concentration of the drug in the serum is less than 100 mg / l, the binding of ceftriaxone to proteins is 95%, and at a concentration of 300 mg / l, only 85%.Due to the lower content of albumins in the interstitial fluid, the concentration of ceftriaxone in it is higher than in serum.
    The half-life is about 8 hours. In newborns up to 8 days and in elderly people older than 75 years, the average half-life is approximately twice as large. In adults, 30-67% of ceftriaxone is excreted unchanged in kidney form, the rest is excreted with bile into the intestine, where it is biotransformed into an inactive metabolite. Under the influence of intestinal flora ceftriaxone turns into an inactive metabolite. In neonates, approximately 70% of the dose administered is excreted by the kidneys. With renal insufficiency or liver pathology in adults, the pharmacokinetics of ceftriaxone is almost unchanged, the half-life period is slightly prolonged. If the kidney function is impaired, the secretion with bile increases, and if liver pathology takes place, then the excretion of ceftriaxone by the kidneys increases.
    Penetration into the cerebrospinal fluid: in newborns and in children with inflammation of the meninges ceftriaxone penetrates into the cerebrospinal fluid, while in the case of bacterial meningitis, an average of 17% of the concentration of the drug in the blood serum diffuses into the cerebrospinal fluid, which is approximately 4 times greater than with aseptic meningitis.24 hours after intravenous administration of ceftriaxone in a dose of 50-100 mg / kg body weight, the concentration in the cerebrospinal fluid exceeds 1.4 mg / l. In adults with meningitis, 2 to 25 hours after the administration of ceftriaxone at a dose of 50 mg / kg body weight, the concentration of ceftriaxone in the cerebrospinal fluid is many times greater than the minimum inhibitory concentrations for the most common meningitis pathogens.
    Indications:Infectious inflammatory diseases caused by susceptible to ceftriaxone pathogens: sepsis, meningitis, infections of the abdominal cavity (peritonitis, inflammatory diseases of the gastrointestinal tract, bile ducts); infection of bones, joints; soft tissues, skin; infection in patients with low immunity; infection of the kidneys and urinary tract, respiratory tract infections (including pneumonia), as well as infections of the ENT organs; urogenital infections (including gonorrhea); pelvic infection, disseminated Lyme borreliosis (early and late stages). Prevention of infections in the postoperative period.
    Contraindications:
    Hypersensitivity to cephalosporins, carbapenems, penicillins. The first trimester of pregnancy.
    Carefully:Hyperbilirubinemia in newborns, premature infants, renal / hepatic insufficiency, ulcerative colitis, enteritis or colitis associated with the use of antibacterial drugs.
    Pregnancy and lactation:The use of the drug in pregnancy (II and III trimesters) is justified only if the expected benefit of therapy for the mother exceeds the potential risk to the fetus. If it is necessary to prescribe the drug during lactation, the question of stopping breastfeeding should be solved. In low concentrations ceftriaxone excreted in breast milk.
    Dosing and Administration:

    The drug is used intramuscularly and intravenously (drip and jet).

    For adults and for children over 12 years old

    The average daily dose is 1-2 g of ceftriaxone once a day or 0.5-1 g every 12 hours. In severe cases or in cases of infections caused by moderately sensitive pathogens, the daily dose can be increased to 4 g.

    For newborns (up to 4 weeks)

    For a single daily dosage, the following regimen is recommended: for newborns (up to 2 weeks of age): 20-50 mg / kg of body weight per day (a dose of 50 mg / kg of body weight is not recommended because of immature neonatal enzyme system).In determining the dose, a distinction should not be made between full-term and preterm neonates.

    For infants (from 4 weeks) and children under 12 years

    The daily dose is 20-80 mg / kg body weight, with: a single injection. Children with a body weight of 50 kg and above should adhere to the dosage for adults. A dose of more than 50 mg / kg body weight should be given as an intravenous infusion, for at least 30 minutes.

    Duration of therapy set individually. As a rule, the administration of the drug should be continued for another 48-72 hours after the temperature is normalized and the eradication of the pathogen is confirmed.

    Meningitis

    In bacterial meningitis in infants and young children, the initial dose is 100 mg / kg of body weight once a day (maximum 4 g). Once it was possible to isolate the pathogenic microorganism and determine its sensitivity, the dose should be reduced accordingly. The best results were achieved with the following periods of therapy:

    Causative agent

    Duration of therapy

    Neisseria meningitidis

    4 days

    Haemophilus influenzae

    6 days

    Streptococcus pneumoniae

    7 days

    Sensitive Enterobacteriacea

    10-14 days

    Gonorrhea

    For the treatment of gonorrhea: 250 mg once intramuscularly.

    Borreliosis Lyme

    50 mg / kg (the highest daily dose is 2 g) for adults and children over 12 years of age once a day for 14 days.

    Prevention of postoperative infections

    Depending on the degree of infectious risk, 1-2 g of ceftriaxone is administered once 30-90 minutes before the operation. In operations on the colon and rectum, simultaneous (but separate) administration of ceftriaxone and one of 5-nitroimidazoles has proved to be well established.

    Lack of kidney and liver function

    In patients with impaired renal function, under the condition of normal liver function, a dose of ceftriaxone is not necessary to reduce. Correction of the dose is required only at creatinine clearance values ​​below 10 ml / min. In this case, the daily dose of ceftriaxone should not exceed 2 g.

    In patients with impaired liver function, if the function of the kidneys is maintained, the dose of ceftriaxone should not be reduced.

    In cases of a combination of severe heathology of the liver and kidneys, the concentration of ceftriaxone in serum should be monitored regularly and, if necessary, adjusted its dosage.

    Patients on dialysis additional introduction of the drug after dialysis is not required.It should, however, control the concentration of ceftriaxone in the serum for possible dose adjustment, since the rate of excretion of the drug in these patients may be reduced.

    Intramuscular injection

    For intramuscular administration, 1 g of the drug should be diluted in 3.5 ml of a 1% solution of lidocaine and inserted deep into the gluteal muscle, trial aspiration helps to avoid unintentional insertion into the blood vessel. It is recommended to inject no more than 1 g of the drug into one buttock. A solution of ceftriaxone diluted with lidocaine can not be administered intravenously, but only intramuscularly.

    Intravenous administration

    For intravenous injection, 1 g of the drug must be diluted in 10 ml of sterile distilled water and administered intravenously slowly for 2-4 minutes.

    Intravenous infusion

    For intravenous infusion of 2 g of the powder should be diluted with approximately 40 ml of a solution free of calcium, such as 0.9% sodium chloride solution, 5% dextrose solution, 10% dextrose solution, 5% fructose solution. Duration of intravenous infusion is at least 30 minutes.

    Side effects:
    Allergic reactions: urticaria, chills or fever, rash, itching, rarely-bronchospasm, eosinophilia, erythema exudative multiforme (incl.Stevens-Johnson syndrome), serum sickness, angioedema, anaphylactic shock.
    On the part of the gastrointestinal tract: nausea, vomiting, diarrhea or constipation, bloating, abdominal pain, taste disturbances, stomatitis, glossitis, pseudomembranous enterocolitis, abnormal liver function (increased activity of "liver" transaminases, less - alkaline phosphatase and bilirubin, cholestatic jaundice ), dysbacteriosis, pseudo-cholelithiasis of the gallbladder ("sludge" - syndrome).
    From the hematopoietic organs: anemia, leukopenia, neutropenia, granulocytopenia, lymphocytopenia, thrombocytosis, thrombocytopenia, hemolytic anemia, hypocoagulation, reduced plasma concentration of coagulation factors (II, VII, IX, X), an elongation of prothrombin time.
    On the part of the urinary system: renal dysfunction (azotemia, increased urea in the blood, hypercreatininaemia, glycosuria, cylindruria, hematuria), oliguria, anuria.
    Local reactions: phlebitis, pain along the vein, soreness and infiltration at the site of the / m introduction.
    Other: headache, dizziness, nosebleeds, candidiasis, superinfection.
    Overdose:Excessively high concentrations of ceftriaxone in plasma can not be reduced by hemodialysis or peritoneal dialysis. Symptomatic measures are recommended for the treatment of overdose cases.
    Interaction:
    Ceftriaxone and aminoglycosides have a synergistic effect on many Gram-negative bacteria. Incompatible with ethanol.
    Ceftriaxone, suppressing the intestinal flora, interferes with the synthesis of vitamin K. With simultaneous administration with drugs that reduce platelet aggregation (non-steroidal anti-inflammatory drugs, salicylates, sulfine pyrazone), the risk of bleeding increases. With simultaneous appointment with anticoagulants, the effect of the latter is noted.
    With simultaneous use with "loop" diuretics and other nephrotoxic drugs, the risk of developing nephrotoxic action increases.
    Ceftriaxone solutions should not be mixed or administered simultaneously with other antimicrobial agents. Ceftriaxone Do not mix with solutions containing calcium.
    Special instructions:
    With long-term treatment, it is necessary to regularly monitor the picture of peripheral blood, indicators of the functional state of the liver and kidneys.
    In rare cases, with ultrasound of the gallbladder, blackouts are observed that disappear after cancellation (even if this phenomenon is accompanied by pain in the right hypochondrium, it is recommended to continue the prescription of the antibiotic and conduct symptomatic treatment).
    During treatment, the use of ethanol is contraindicated - disulfiramrpoid effects (red face, nausea, vomiting, headache, lowering of blood pressure, tachycardia, dyspnea) are possible.
    It is impossible to exclude the possibility of developing an anaphylactic shock, which requires immediate therapy - first intravenously injected epinephrine, then glucocorticoids.
    In vitro studies have shown that, like other cephalosporin antibiotics ceftriaxone is able to displace bilirubin, associated with serum albumin. Therefore, in newborns with hyperbilirubinemia and, especially, in preterm infants, the use of ceftriaxone requires even greater caution. Elderly and debilitated patients may require the appointment of vitamin K.
    Form release / dosage:
    Powder for solution for intravenous and intramuscular injection 1.0 g.
    Packaging:
    By 1.0 g in a bottle of 15 ml of clear glass, sealed with a gray stopper made of butyl rubber, crimped aluminum ring.
    1 bottle with instructions for use in a cardboard box.
    Storage conditions:In dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    3 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-004519/08
    Date of registration:10.06.2008
    The owner of the registration certificate:Mekofar Chemical-Pharmaceutical Joint Stock CompanyMekofar Chemical-Pharmaceutical Joint Stock Company Vietnam
    Manufacturer: & nbsp
    Representation: & nbspDominanta-Service CJSCDominanta-Service CJSC
    Information update date: & nbsp24.11.2015
    Illustrated instructions
      Instructions
      Up